IQVIA Laboratories
IQVIA Laboratories is the central laboratory and specialty biomarker division of IQVIA Holdings, providing clinical-trial lab testing across genomics, flow cytometry, bioanalytical, anatomic pathology, and companion diagnostics to pharmaceutical and biotech sponsors operating in more than 100 countries.
- Company typePublic
- Founded2016
- HeadquartersResearch Triangle Park, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What IQVIA Laboratories does
IQVIA Laboratories is the central laboratory and specialty biomarker services division of IQVIA Holdings Inc. (NYSE:IQV), providing drug discovery and clinical development laboratory services to pharmaceutical and biotech sponsors globally. The unit operates facilities in Research Triangle Park NC (headquarters), Valencia CA, Marietta GA, Edinburgh UK, Beijing, and Tokyo, plus a partner laboratory in South Africa, and employs approximately 2,762 people. Service lines span Central Laboratory Services, Bioanalytical Laboratories, Clinical Genomics, Discovery Sciences, Biomarker Services, Flow Cytometry, Anatomic Pathology, Companion Diagnostics, Vaccine Laboratory Services, Pediatric Drug Development, and PBMC/BMMC processing, supported by a validated menu of more than 3,500 tests and assays with more than 450 new assays validated since 2015.
The technology stack combines proprietary digital platforms (Site Lab Navigator e-Requisition suite launched March 2025; Laboratory Trial Management System using AI and OCR) with advanced instrument deployments including Cytek Aurora 5-laser spectral flow cytometers across seven labs and Illumina next-generation sequencing. The company has more than 12 years and 150+ engagements in companion diagnostics, and its Translational Science and Innovation Laboratory (TSAIL) bridges pre-clinical research and early clinical trials using AI/ML for whole slide imaging and emerging biomarker modalities such as RNAScope and Nanostring GeoMX.
IQVIA Laboratories sells primarily through enterprise B2B field sales and dedicated project management, generating revenue via project-based contracts for clinical trial laboratory testing with biopharma sponsors, biotech companies, medical device firms, and diagnostic companies across North America, Europe, Asia-Pacific and China. Operations are reported within IQVIA's larger Research & Development Solutions segment; IQVIA Laboratories does not separately disclose revenue. The unit leverages IQVIA's broader clinical research footprint for distribution and customer relationships, while internal operations benefit from harmonized SOPs, 24-hour global PBMC transit, 98-99% on-time delivery performance, and consecutive Vaccine Industry Excellence Awards for Best Central/Specialty Laboratory in 2024 and 2025.
IQVIA Laboratories firmographics
Firmographics- Name
- IQVIA Laboratories
- Legal name
- IQVIA
- Website
- https://labs.iqvia.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- IQVIA Laboratories is the central laboratory and specialty biomarker division of IQVIA Holdings, providing clinical-trial lab testing across genomics, flow cytometry, bioanalytical, anatomic pathology, and companion diagnostics to pharmaceutical and biotech sponsors operating in more than 100 countries.
- Ownership category
- akta.pro rank
IQVIA Laboratories industry classification
Industry- Product category
- Clinical Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
- akta.pro secondary industries
- Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Clinical Research & Trial Central Laboratories (HLAFAMAL), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where IQVIA Laboratories is headquartered
LocationHeadquarters
- HQ city
- Research Triangle Park
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
IQVIA Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Clinical Laboratory Services: Provides comprehensive central laboratory and specialty biomarker services to pharmaceutical and biotech companies for drug discovery and development. Revenue is generated through project-based contracts for clinical trial laboratory testing services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
IQVIA Laboratories product offering
Product offeringCore offering
IQVIA Laboratories provides comprehensive central laboratory and specialty biomarker services that support drug discovery and clinical development for pharmaceutical and biotechnology sponsors. Services span genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays, ADME and bioanalytical testing, delivered through a global harmonized laboratory network with dedicated project management.
Product overview
IQVIA Laboratories is a global leader in drug discovery and development laboratory services offering a comprehensive suite of central laboratory and specialty biomarker services. The portfolio is organized as a modular platform with Central Laboratory Services as the core foundation, supplemented by specialized service modules including Bioanalytical Laboratories (pharmacokinetics, ADME, biomarker analysis), Clinical Genomics Laboratory, Discovery Sciences, Translational Science and Innovations Laboratory Services (TSAIL), Flow Cytometry Services, Anatomic Pathology, Companion Diagnostics, Vaccine Laboratory Services, Biomarker Services, and Pediatric Drug Development Services. Digital technology offerings include Site Lab Navigator (e-Requisition innovation) and the Laboratory Trial Management System (LTMS). Specialized offerings for biotech customers and comprehensive project management support complete the portfolio. The company supports every phase of drug discovery and development across diverse regions and regulatory frameworks.
Differentiator
Problem solved
Functional benefit
Products and services
- Central Laboratory Services Comprehensive central laboratory testing services for clinical trials including chemistry, coagulation, hematology, immunoassays, microbiology, molecular assays, and specialized esoteric tests for pharmaceutical and biotech sponsors.
- Bioanalytical Laboratories Bioanalytical services including pharmacokinetics, drug metabolism (ADME), biomarker analysis, and biosimilar testing using LC-MS bioanalysis, LC-MS/MS, hybrid LC-MS, and immunoassay methodologies.
- Clinical Genomics Laboratory Global genomic testing services supporting drug discovery, precision medicine, and clinical development including DNA/RNA genetic profiling, solid tumor molecular minimal residual disease analysis, and clinical variant curation.
- Discovery Sciences Early-stage research laboratory services focused on biomarker discovery and assay development, facilitating technology transfers from sponsors and developing novel biomarkers for clinical trial deployment.
- Biomarker Services Specialty biomarker services including small and large molecule LC-MS biomarker analysis, immunoassay biomarker methods, and custom biomarker panel development for precision medicine applications.
- Vaccine Laboratory Services Specialized laboratory services for vaccine development including COVID-19 clinical trial solutions, infectious disease testing, and vaccine efficacy assessments with global regulatory compliance.
- Translational Science and Innovations Laboratory Services (TSAIL) Translational biomarker solutions accelerating assay adoption into clinical trials through new technology evaluation, early biomarker discovery, and AI/ML-enhanced digital pathology analytics.
- Flow Cytometry Services High-parameter flow cytometry services for immune monitoring including custom panel design, spectral flow cytometry using Cytek Aurora instruments, and intracellular cytokine staining assays.
- Anatomic Pathology Laboratory Services Anatomic and molecular pathology services including histopathologic diagnostics, immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and AI-enhanced digital imaging analytics.
- Companion Diagnostics (CDx) Companion diagnostics development and testing services supporting CDx submissions with global regulatory experience across APAC, China, EMEA, and US regions, including IHC, NGS, and PCR technologies.
- Pediatric Drug Development Services Specialized pediatric sample collection, handling, and testing services with micro-sampling capabilities and low volume blood sample requirements optimized for pediatric clinical trials.
- Central Laboratory PBMC and BMMC Services Global processing of peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMMCs) with standardized procedures ensuring consistent yields, viability, and recovery across the global laboratory network.
- Clinical Laboratory Project Management Clinical trial project management services with dedicated project managers, Laboratory Trial Management System (LTMS), and 98-99% on-time delivery performance for clinical trial execution.
- Immunoassay and Immunogenicity Services Ligand-binding immunoassay development and validation services for pharmacokinetics, immunogenicity (ADA and Nab), and biomarker assays supporting biotherapeutic studies across the drug development continuum.
- Quantitative Assays for Peptides using LC-MS Quantitative peptide analysis using high-resolution mass spectrometry (HRMS) and nano-scale LC for peptide therapeutics and biomarkers, including cytokines, insulins, natriuretic peptides, and therapeutic peptides for multiple therapeutic areas.
- Biotech Laboratory Solutions Flexible laboratory solutions customized for small and mid-size biotech companies including dedicated project leadership, scientific expertise, and access to global laboratory network.
- Flow Cytometry Assay Development Dedicated assay development laboratories providing custom flow cytometry panel design, feasibility assessment, and 8-12-week validation periods for novel biomarker and therapeutic assays.
- Validated Bioanalytical Assays Validated bioanalytical assays for small molecules and biomarkers including over 135 proprietary and non-proprietary methods covering pharmacokinetics, drug metabolism, and biomarker analysis.
- Site Lab Navigator Advanced e-Requisition solution that enables investigator sites to submit lab requisitions and manage specimens electronically, eliminating paper-based processes with real-time sample tracking, guided kit replacement, and real-time data validation.
- Laboratory Trial Management System (LTMS) Clinical Trials Management System utilizing AI and optical character recognition for automation and efficiency, managing all clinical trial components from one system with sample-centric approach.
Quantifiable outcome
- 96% of deliveries agreed to be shipped within 24h arrive on time
- +1 more outcomes
Companies that use IQVIA Laboratories
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
IQVIA Laboratories technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
IQVIA Laboratories partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- CEPI (Coalition for Epidemic Preparedness Innovations)coreLuc Gagnon, IQVIA Laboratories' global head of vaccine sciences, appointed to CEPI's Global Central Laboratory Network Advisory Council, strengthening the partnership in global vaccine development and epidemic preparedness.
- IlluminacoreQ2 Solutions (affiliated laboratory) strengthened scalable, next generation sequencing approaches with Illumina's NovaSeq X Plus platform solution, enhancing data quality and analysis capabilities with sustainable operations.
- University of Texas Medical Branch (UTMB)coreCollaboration to develop a novel assay for COVID-19 (SARS-CoV-2) tests to drive rapid development of a Coronavirus vaccine. Once viable assay developed, produced for use in clinical trials to determine vaccine effectiveness.
- Cytek BiosciencescoreMulti-year collaboration for deployment of next generation flow cytometry systems (Cytek Aurora) in seven laboratories globally plus partner laboratory in South Africa. Cytek 5 Laser Aurora instruments selected for exceptional capabilities in fluorochrome independence and full spectrum sensitivity.
- Illumina (for CDx)corePartnership for Tumor Mutational Burden (TMB) analysis via relationship with partner Illumina using TSO 500 NGS gene panel for companion diagnostics.
- IVD Companies (In-Vitro Diagnostic)coreWork with IVD companies who provide developed assays that are tested at central labs following verification of performance. Central labs are qualified by IVD partner companies following Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
IQVIA Laboratories competitors and assessment
Company assessmentBroad incumbents
- Syneos Health: Syneos Health is a CRO that operates central lab and bioanalytical services alongside broader clinical development offerings, competing with IQVIA Laboratories for integrated biopharma trial laboratory mandates.
- Charles River Laboratories: Charles River provides discovery, safety assessment and bioanalytical/CRO lab services to biopharma; while more discovery-leaning, it overlaps with IQVIA Laboratories in bioanalytical and specialty lab testing for drug development.
- PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher Scientific, offers clinical research and central laboratory services as part of a broader CRO/biopharma services platform, with overlapping capabilities in bioanalytical and specialty biomarker testing for trials.
Direct peers
- ICON Central Laboratories: ICON plc operates a global central laboratory network (formerly PRA Health's lab) supporting clinical trials with similar assay menus and regional reach, competing directly for biotech and large-pharma central lab mandates.
- Q² Solutions: Q² Solutions is a central/bioanalytical laboratory joint venture between IQVIA and Quest Diagnostics, providing genomics, bioanalytical, flow cytometry and immunoassay services for clinical trials - effectively a sister entity and head-to-head competitor in clinical trial lab services.
- Eurofins Central Laboratory: Eurofins Central Laboratory provides global clinical trial central lab services including immunology, molecular diagnostics and bioanalytical testing, with broad geographic coverage comparable to IQVIA Laboratories' multi-region footprint.
- Labcorp Central Laboratory Services: Labcorp operates one of the largest global central and specialty laboratories serving clinical trials, offering bioanalytical, genomics, flow cytometry and esoteric testing to biopharma sponsors - directly comparable to IQVIA Laboratories across the core central lab stack.
- SGS Health Sciences (SGS Nutrasource): SGS operates a global central laboratory network providing bioanalytical, immunogenicity and biomarker services to pharma and biotech clients - directly comparable to IQVIA Laboratories in routine and specialty clinical trial testing.
Emerging players
- Medpace Holdings: Medpace is a mid-size CRO with embedded central laboratory and biomarker capabilities serving biotech sponsors, competing in a more focused segment than IQVIA Laboratories but addressing overlapping trial lab needs.
Regional players
- Frontage Laboratories: Frontage is a US/China-headquartered CRO with bioanalytical and CMC/laboratory services for drug development; comparable lab services but with a stronger Asia-Pacific footprint that overlaps with IQVIA Labs' Beijing/Tokyo operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights8 records
Customer concentration
IQVIA Laboratories social profiles
Digital presenceIQVIA Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
IQVIA Laboratories leadership team
Management profileNumber of profiles
Profiles2 records
IQVIA Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IQVIA Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IQVIA Laboratories
What does IQVIA Laboratories do?
IQVIA Laboratories provides comprehensive central laboratory and specialty biomarker services that support drug discovery and clinical development for pharmaceutical and biotechnology sponsors. Services span genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays, ADME and bioanalytical testing, delivered through a global harmonized laboratory network with dedicated project management.
Is IQVIA Laboratories a public or private company?
IQVIA Laboratories is a public company. It is classified as corporate owned and is currently operating.
When was IQVIA Laboratories founded?
IQVIA Laboratories was founded in 2016. It employs 1,001 to 5,000 people.
Where is IQVIA Laboratories based?
IQVIA Laboratories is headquartered in Research Triangle Park, United States, in the North America region.
How does IQVIA Laboratories make money?
One revenue line is on record: clinical Laboratory Services.
Who are IQVIA Laboratories's main competitors?
Broad incumbents on record are Syneos Health, Charles River Laboratories and PPD (Thermo Fisher Scientific). Direct peers are ICON Central Laboratories, Q² Solutions, Eurofins Central Laboratory, Labcorp Central Laboratory Services and SGS Health Sciences (SGS Nutrasource). Medpace Holdings is listed as an emerging player. Frontage Laboratories is listed as a regional player.
Does IQVIA Laboratories have an API?
No public API is recorded for IQVIA Laboratories.
What industry is IQVIA Laboratories in?
IQVIA Laboratories's product category is Clinical Laboratory Services. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.